At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 249 enrolled
Drug / intervention
Mencevax ACWYbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentric, Surveillance Study to Monitor Safety of GSK Biologicals' Purified Meningococcal Polysaccharide Vaccine of Serogroups ACWY in 3,000 Filipino Subjects Aged Above 2 Years When Administered According to the Prescribing Information.
In Brief
A Phase 4 clinical trial evaluating Mencevax ACWY for Infections, Meningococcal. Completed, enrolled 249 participants across 8 sites.
Detailed Summary
GlaxoSmithKline Philippines has submitted a registration file for its Purified Meningococcal Polysaccharide of Serogroup ACWY Vaccine (Mencevax ACWY). This study is being conducted to collect clinical data in the local target population in order to assess the occurrence of rare adverse events after vaccination as per the requirement of Philippines Bureau of Food and Drugs Directive.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Meningococcal
CountriesPhilippines
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedFeb 2006
Primary CompletionOct 2006
Study CompletionOct 2006
TodayJul 2026
First PostedFeb 13, 2006
Enrollment StartJan 14, 2006
Primary CompletionOct 1, 2006
Study CompletionOct 17, 2006
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 20.4 years ago
Interventions
Mencevax ACWYbiological
1 subcutaneous injection.